Research Article

Evaluation of Desmin, α-SMA and hTERT expression in pulmonary fibrosis and lung cancer

Farahnaz Fallahian*, Seyed Ali Javad Moosavi, Frouzandeh Mahjoubi, Samira Shabani, Pegah Babaheidarian and Tayebeh Majidzadeh

Published: 01/23/2018 | Volume 3 - Issue 1 | Pages: 001-009


Background: Pulmonary fibrosis is a clinical problem with an enigmatic etiology with no effective therapy. Current therapies for lung fibrosis are ineffective for progression of lung fibrosis and preventing respiratory failure.

Objectives: The aim of this study is to explore the expression of Desmin, α-smooth muscle actin (α-SMA) and the telomerase subunit: human telomerase reverse transcriptase (h-TERT) in a spectrum of lung tissue samples consist of lung fibrosis, lung cancer, and healthy controls.

Materials and Methods: The expression of Desmin, α-SMA and hTERT were studied in samples of 15 pulmonary fibrosis samples, 16 samples of lung cancer and 14 healthy controls investigated. We evaluated Desmin, α-SMA as well as the expression of components of telomerase (TERT), by methods: RNA Extraction and cDNA synthesis, Real-Time quantitative PCR, Immunohistochemistry, all prepared from lung tissue paraffin blocked.

Results: α-SMA marker detected 1(8.3%) of healthy control and 11(91.7%) of lung fibrosis samples. The difference between groups was significant (p<0.001). Also the difference between healthy control 1(6.7%) and lung cancer 14 (93.3%) for α-SMA marker was a significant (P<0.001). It was a significant difference between healthy control and lung cancer for TERT expression (P=.005). TERT was not positive in any sample of neither healthy control nor lung fibrosis. For TERT, it was a significant difference between lung fibrosis and lung cancer by Fisher’s Exact Test (P=.004). Expression of TERT and α-SMA between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) was not statistically significant (P=.700, P=0758), respectively.

Conclusions: We recommend more investigation to regard α-SMA, Desmin in patients with lung fibrosis and follow them for possible cancer risk. Also, more study is needed to regard TERT as a marker in lung cancer. Assessment of these markers may have future implication to explain the same way of pathogenesis and carcinogenesis of fibrosis and cancer and for prevention or treatment

Read Full Article HTML DOI: 10.29328/journal.jcicm.1001011 Cite this Article


  1. Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis.  Annu Rev Med. 2013; 64: 265-276. Ref.:
  2. Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med. 2015; 21: 626-633. Ref.:
  3. Kottmann RM, Hogan CM, Phipps RP, Sime PJ. Determinants of initiation and progression of idiopathic pulmonary fibrosis . Respirology. 2009; 14: 917-933. Ref.:
  4. Gu L, Zhu YJ, Yang X, Guo ZJ, Xu WB, et al. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation.  Acta Pharmacol Sin. 2007; 28: 382-391 . Ref.:
  5. Schissel SL, Layne MD .   Telomerase, myofibroblasts, and pulmonary fibrosis. Am J Respir Cell Mol Biol. 2006; 34: 520-522. Ref.:
  6. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations.  PLoS One. 2010; 19: 5. Ref.:
  7. Calado RT. Telomeres in lung diseases. Prog Mol Biol Transl Sci. 2014; 125: 173-183. Ref.:
  8. Trăilă D, Mlădinescu OF, Oancea C, Tudorache V. Short telomeres in pulmonary fibrosis: from genetics to clinical significance. Pneumologia. 2015; 64: 11-13 . Ref.:
  9. Tsang AR, Wyatt HD, Ting NS, Beattie TL. hTERT mutations associated with idiopathic pulmonary fibrosis affect telomerase activity, telomere length, and cell growth by distinct mechanisms. Aging Cell. 2012; 11: 482-490. Ref.:
  10. Garcia CK. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc. 2011; 8: 158-162. Ref.:
  11. Liu T, Ullenbruch M, Young Choi Y, Yu H, Ding L, et al. Telomerase and telomere length in pulmonary fibrosis . Am J Respir Cell Mol Biol. 2013; 49: 260-268. Ref.:
  12. Antoniou KM, Margaritopoulos GA, Proklou A, Karagiannis K, Lasithiotaki I, et al. Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP. J Inflamm (Lond). 2012; 9: 27. Ref.:
  13. Li J, Yang M, Li P, Su Z, Gao P, et al. Idiopathic pulmonary fibrosis will increase the risk of lung cancer. Chin Med J (Engl). 2014; 127: 3142-3149 . Ref.:
  14. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011; 157: 191-199. Ref.:
  15. Hyldgaard C. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.  Dan Med J. 2015; 62: 5069. Ref.:
  16. Antoniou KM, Samara KD, Lasithiotaki I, Margaritopoulos GA, Soufla G, et al. Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer . Oncol Rep. 2013; 30: 2617-2624. Ref.:
  17. Fernandez-Garcia I, Ortiz-de-Solorzano C, Montuenga LM. Telomeres and telomerase in lung cancer. J Thorac Oncol. 2008; 3:1085-1088. Ref.:
  18. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst. 1995; 87: 895-902 . Ref.:
  19. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol.  1999; 180: 10-18 . Ref.:
  20. Lantuejoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer. 2007; 120: 1835-1841. Ref.:
  21. Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway . Neoplasia. 2007; 9: 840-852 . Ref.:
  22. Yan Wang, Yiting Liu, Qinghua Zhang, Rong Gao, Ke Wang. IPF and lung cancer: homologous but different endings, the progress in the correlation research. Int J Clin Exp Med. 2017; 10:4319-4329. Ref.:
  23. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, mo-lecular mechanism, and therapeutic interven¬tion. J Am Soc Nephrol. 2004; 15: 1-12. Ref.:
  24. Pozharskaya V, Torres-Gonzalez E, Rojas M, Gal A, Amin M, et al. Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis. PLoS One. 2009; 4: 7559. Ref.:
  25. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-454. Ref.: